- Home
- CCBG vs SPRY Comparison
CCBG vs SPRY Comparison
Compare CCBG & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCBG | SPRY |
|---|---|---|
| Founded | 1895 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.7M | 860.0M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CCBG | SPRY |
|---|---|---|
| Price | $41.47 | $8.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $45.00 | $40.00 |
| AVG Volume (30 Days) | 72.3K | ★ 1.0M |
| Earning Date | 04-20-2026 | 03-09-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 3.60 | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $6.25 | $109.11 |
| Revenue Next Year | $3.17 | $91.00 |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.38 | $6.66 |
| 52 Week High | $46.83 | $18.63 |
Technical Indicators
Market Signals| Indicator | CCBG | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 39.75 |
| Support Level | $38.77 | $8.05 |
| Resistance Level | $41.86 | $9.46 |
| Average True Range (ATR) | 1.12 | 0.45 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 17.45 | 26.34 |
Price Performance
Historical ComparisonAbout CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.